This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / BioArctic issued 5,000 shares
Business share issuance

BioArctic issued 5,000 shares

Analysis based on 6 articles · First reported May 29, 2026 · Last updated May 30, 2026

Sentiment
0
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The issuance of 5,000 Class B shares by BioArctic is a routine event related to its stock option program. This action has a minimal direct impact on the market, as it is a small increase in the total number of shares and votes for BioArctic.

biotechnology pharmaceuticals
Event Summary

BioArctic AB (publ) announced the issuance of 5,000 Class B shares during May 2026. These shares were issued for delivery to participants in the company's 2019/2028 stock option program, following an exercise of 5,000 stock options of series 2019/2028. As of May 29, 2026, the total number of shares in BioArctic amounted to 88,724,485, comprising 74,324,489 listed Class B shares and 14,399,996 unlisted Class A shares. The total number of votes in BioArctic is 218,324,449. This information was disclosed by BioArctic pursuant to the European Union Market Abuse Regulation.

Entities Involved
stock
BioArctic
BioArctic issued 5,000 Class B shares to participants in its stock option program, increasing its total number of shares and votes.
Importance 100.0 Sentiment 0.0
exch
Nasdaq Stockholm
Nasdaq Stockholm is the exchange where BioArctic's Class B shares are listed.
Importance 20.0 Sentiment 0.0
stock
Eisai
Eisai is mentioned as BioArctic's partner in developing and commercializing Leqembi.
Importance 10.0 Sentiment 0.0
alliance
European Union
The European Union's Market Abuse Regulation obliges BioArctic to disclose this information.
Importance 10.0 Sentiment 0.0
Relationships
BioArctic licensor ↔ Eisai BioArctic is the original developer and licensor of the Alzheimer's drug Leqembi, receiving royalties from Eisai's globa
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.